High resolution analysis of the human transcriptome: detection of extensive alternative splicing independent of transcriptional activity by Zhou, Weiyin et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Genetics
Open Access Methodology article
High resolution analysis of the human transcriptome: detection of 
extensive alternative splicing independent of transcriptional activity
Weiyin Zhou1, Margaret A Calciano1, Heather Jordan1, Michael Brenner1, 
Seth Johnson1, Darong Wu1, Lin Lei1, Diego Pallares2, Pascale Beurdeley2, 
Fabien Rouet2, Pritmohinder S Gill1, Laurent Bracco2, Cyril Soucaille2 and 
Richard Einstein*1
Address: 1ExonHit Therapeutics Inc, 217 Perry Parkway, Bldg 5, Gaithersburg, MD, 20877 USA and 2ExonHit Therapeutics SA, 65, blvd Massena 
F-75013 Paris, France
Email: Weiyin Zhou - Weiyin.Zhou@exonhit.com; Margaret A Calciano - Margaret.Calciano@exonhit.com; 
Heather Jordan - Heather.Jordan@exonhit.com; Michael Brenner - Mike.Brenner@exonhit.com; Seth Johnson - Seth.Johnson@exonhit.com; 
Darong Wu - Darong.Wu@exonhit.com; Lin Lei - Lin.Lei@exonhit.com; Diego Pallares - Diego.Pallares@exonhit.com; 
Pascale Beurdeley - Pascale.BEURDELEY@exonhit.com; Fabien Rouet - Fabien.ROUET@exonhit.com; 
Pritmohinder S Gill - Pritmohinder.Gill@exonhit.com; Laurent Bracco - Laurent.BRACCO@exonhit.com; 
Cyril Soucaille - Cyril.SOUCAILLE@exonhit.com; Richard Einstein* - Richard.Einstein@exonhit.com
* Corresponding author    
Abstract
Background: Commercially available microarrays have been used in many settings to generate expression profiles for a variety
of applications, including target selection for disease detection, classification, profiling for pharmacogenomic response to
therapeutics, and potential disease staging. However, many commercially available microarray platforms fail to capture transcript
diversity produced by alternative splicing, a major mechanism for driving proteomic diversity through transcript heterogeneity.
Results: The human Genome-Wide SpliceArray™ (GWSA), a novel microarray platform, utilizes an existing probe design
concept to monitor such transcript diversity on a genome scale. The human GWSA allows the detection of alternatively spliced
events within the human genome through the use of exon body and exon junction probes to provide a direct measure of each
transcript, through simple calculations derived from expression data. This report focuses on the performance and validation of
the array when measured against standards recently published by the Microarray Quality Control (MAQC) Project. The array
was shown to be highly quantitative, and displayed greater than 85% correlation with the HG-U133 Plus 2.0 array at the gene
level while providing more extensive coverage of each gene. Almost 60% of splice events among genes demonstrating differential
expression of greater than 3 fold also contained extensive splicing alterations. Importantly, almost 10% of splice events within
the gene set displaying constant overall expression values had evidence of transcript diversity. Two examples illustrate the types
of events identified: LIM domain 7 showed no differential expression at the gene level, but demonstrated deregulation of an exon
skip event, while erythrocyte membrane protein band 4.1 -like 3 was differentially expressed and also displayed deregulation of
a skipped exon isoform.
Conclusion: Significant changes were detected independent of transcriptional activity, indicating that the controls for transcript
generation and transcription are distinct, and require novel tools in order to detect changes in specific transcript quantity. Our
results demonstrate that the SpliceArray™ design will provide researchers with a robust platform to detect and quantify specific
changes not only in overall gene expression, but also at the individual transcript level.
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Background
A large portion of the diversity within the transcriptome is
generated by alternative splicing, which in some cases, can
produce thousands of transcripts from a single gene or
locus [1,2]. This has important implications in biology
and pathophysiology where extensive alterations in tran-
scripts resulting from alternative splicing produce struc-
turally different products and impacts the function of
genes in biology, disease [3-6], as well as processes such as
evolution [7,8]. The fine granularity of the transcriptome
has not been determined with clarity, and new commer-
cial tools are required in order to begin to identify with
certainty the diverse content of the transcriptome. Tradi-
tional microarray designs and analytical methods are not
robust enough to detect this transcript diversity. SpliceAr-
ray™ microarrays were developed to experimentally define
the composite of transcripts that are present within bio-
logical samples and have the ability to detect subtle differ-
ential changes in gene expression for different
alternatively spliced isoforms. The performance parame-
ters of the human Genome-Wide SpliceArray™ (GWSA)
which monitors over 280,000 potential splicing events
(known and predicted) were assessed here, guided by the
recent publications from the MicroArray Quality Control
(MAQC) consortium.
The MAQC project [9] is a FDA sponsored consortium
founded to address concerns of microarray reproducibil-
ity of expression profiling experiments. The purpose was
to generate quality control tools for the microarray com-
munity in order to avoid procedural failures and to
develop guidelines for microarray data analysis by provid-
ing the public with large reference datasets along with
readily accessible reference RNA samples. The study
found, that overall, the platforms perform similarly [9]
and were validated with alternative quantitative gene
expression platforms [10]. However, all the platforms
tested contain a similar bias where probes were designed
to monitor the overall level of the gene, and do not give
any expression information toward the isoform diversity
produced from each gene through alternative splicing.
Here we present a novel microarray platform and analysis
for the efficient detection of isoform diversity on a
genome wide scale in human. Our analysis of this new
microarray design is in accordance with the approach out-
lined by the MAQC consortium and demonstrates that the
SpliceArray™ products are highly reproducible, quantify
transcripts, and are sensitive in detecting subtle changes in
transcript ratios.
Results
Alternative splicing events were identified through a com-
parison of sequence data from the NCBI GenBank data-
base. A total of 20,649 human genes were selected and
analyzed for representation on the human Genome-Wide
SpliceArray™ (GWSA). From this group, 19,066 genes or
92.3% were found to contain evidence of potential alter-
native splicing within the selected sequence collection.
Table 1 lists the complete distribution of the different
event types identified and included on the GWSA. For
each splice event a series of probe sets (F, T, B, C, D, and
E) consisting of up to three probes per probe set were gen-
erated to detect different transcripts or isoforms (Addi-
tional file 1; [11,12]). In addition to the F, T, B, C, D and
E probe sets that monitor the ~138,000 cDNA evidenced
splice events and ~142,000 predicted exon skip events, a
series of structural probe sets are included on the human
GWSA that monitor ~176,000 exon-intron boundaries for
novel alterations (Additional file 1; Table 1).
To assess performance of the human GWSA, samples were
selected in accordance with the MAQC project, which
included human universal reference RNA (Sample A),
human brain RNA (Sample B) and two titration samples
Table 1: Distribution of splice events from an analysis of the human genome.
Event Type Number of events
Total putative alternative splicing events with cDNA supporting evidence: 138,636
▪ novel exon 46,352
▪ novel exons 9,413
▪ exon skipped 31,163
▪ exons skipped 11,905
▪ alternative splice donor (ASD) 10,281
▪ alternative splice acceptor (ASA) 12,606
▪ intron retention 5,999
▪ novel intron 10,917
Predictions of single exon skips with no supporting cDNA evidence 142,697
Intron/exon boundary regions with structural probes for prediction of ASA, ASD and intron retentions 176,000
Results from the human genome analysis of splicing events from 20,649 genes are tabulated according to the type of splice event. All events 
included here are monitored on the human GWSA. The alternative splicing results for the complete transcriptome data set are available online at 
http://portal.splicearray.com.BMC Genetics 2009, 10:63 http://www.biomedcentral.com/1471-2156/10/63
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(C and D; see methods; refer to fig. 1 in [13]). As with the
MAQC project [13], we assumed a linear response for
each probe across the four titration samples (A-D). The
frequency distribution of the expression values for all 12
arrays (samples A-D run in triplicate) showed a normal
distribution of signal as expected for the platform (Addi-
tional file 2-A). The reproducibility of the arrays was
found to be highly concordant and produced low coeffi-
cients of variation (CV%) for each sample analyzed. The
mean CV% were found to be slightly higher than the
median values (5.5 versus 4.23, respectively), indicating a
slight bias towards higher values. On a gross level, princi-
pal component analysis (Additional file 2-B) showed
close grouping of the replicates.
The titration samples were analyzed at the probe set, gene,
and event level to define the quantitative nature of the
expression data generated by the array. After filtering low-
expressing probe sets, 527,574 probe sets were identified
in which expression was higher in the universal sample
(A) than in the brain sample (B) (A>B) and 472,085
probe sets where B>A. Based on the fold change between
samples A and B, probe sets were assessed for a correct
titration response of expression values such that where the
probe set showed a fold change of A > B, that it also dem-
onstrated that sample A > sample C > sample D > sample
B. Where probe sets were found to be B > A, calculations
were made to identify probe sets were B > D > C > A. Exon
body probe sets demonstrated the ability to titrate slightly
more efficiently than junction probe sets for both groups
and were more efficient in detecting the proper response
(Figure 1).
The probe set configuration was used to generate total
gene level expression values which were calculated from
the array data using the probes F and T which are common
to most isoforms of the gene and as such represent all
common features for all transcripts at a locus. On average,
87% of genes that were significantly differentially
expressed between samples A and B (p < 0.001) and had
greater than a 2.0 fold change demonstrated correct titra-
tion of all four samples (Figure 2), indicating the array
quantifies gene expression at the gene level in an accurate
manner. In addition, we compared gene expression levels
from data generated on the GWSA to a more conven-
tional, 3' biased microarray, the Affymetrix HG-U133 Plus
2.0 GeneChip. The Affymetrix HG-U133 Plus 2.0 Gene-
Chip data set taken from the MAQC Project included only
12,091 genes [13] which were mapped back to our data
on the human GWSA. Comparison of the annotations
from each array provided 11,089 out of a possible 12,091
genes in common which was reduced to 7,147 genes after
removing genes exhibiting low expression. As expression
values generated on different platforms cannot be directly
compared due to different platform parameters, labeling
methods, probe sequences, etc., we compared the relative
expression difference between samples A and B. The log
ratio of sample A versus sample B for all genes was highly
Titration analysis of probe set response Figure 1
Titration analysis of probe set response. Probe sets were selected for analysis based on the expression results detecting 
different transcripts. Probe sets were binned based on the fold change between samples A (universal reference) and B (total 
brain), and assessed for correct titration of expression values for samples A, B, C, and D. Probe sets were filtered statistically 
and those with p values < 0.001 were analyzed. Probe types were separated according to exon body and junction probes. The 
left graph indicates probe sets which were more highly expressed in sample A than sample B (A > B), and the right graph dis-
plays probe sets which were more highly expressed in sample B versus sample A (B > A).
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correlated between the two platforms with a linear corre-
lation of 0.85 (Figure 3, Table 2). When considering genes
that showed a 2 fold change between samples, the coeffi-
cient rose to 0.90, and continued to rise as the fold change
increased (Table 2), indicating that the human GWSA pro-
vides highly concordant quantification of gene expression
when compared to the Affymetrix HG-U133 Plus 2.0
GeneChip.
The human GWSA has the added ability to detect alterna-
tively spliced genes due to the extensive design of the
probes on the array, so besides measuring gene expression
levels, individual splicing events can also be monitored
on the array. To investigate the degree of splicing altera-
tions among genes with and without differential gene
expression between samples A and B, the set of genes
identified as expressed above background were filtered
into two groups. One group consisted of genes not differ-
entially expressed between samples A and B (fold changes
within the range of -1.2 ≤ x ≤ 1.2), and the other included
genes with a greater than 3-fold change (x ≤ -3 or x ≥ 3)
between samples. In order to determine the extent of dif-
ferential splicing that occurred within the two gene cate-
gories, a splicing ratio was calculated that consisted of the
long form-specific probe set (B) divided by the short
form-specific probe set (E) (Additional File 1), called the
B/E ratio, and events that had 3-fold change or greater in
this ratio between samples A and B were identified. Exten-
sive alternative splicing activity was identified in both
groups (Table 3). Those genes that showed high level of
differential expression at the gene level (greater than 3
fold change) included 1,844 genes with 13,323 potential
splicing events contained within these genes. Of these
potential events, 59% (7833) of the events had B/E ratios
that were differentially expressed by greater than 3 fold
indicating a change in the isoforms for these genes (Table
3). The second category incorporated genes where no
overall differential expression change was detected at the
gene level (less than 1.2 fold change between the samples
A and B), but splicing alterations were identified. 4,434
genes were included within this group and contained
32,917 potential splicing events. 9% (3012) of these
events displayed a 3 fold expression change in the B/E
ratio suggesting that significant splicing changes were
detected in groups of genes regardless of their overall gene
expression characteristic demonstrating that transcription
and alternative splicing are independent events (Table 3).
Within this category of events, approximately 56% were
exon(s) skip events and 26% were novel exon events. The
other 18% consisted of events detecting intron retentions,
novel introns, and alternative splice donor and acceptors.
Worth noting, analysis of splice events regardless of the
gene expression level revealed that greater than 72% of the
splice events that were significantly differentially
expressed between samples A and B titrated all four sam-
ples correctly further demonstrating the extensive quanti-
fication available on the array (data not shown).
In order to validate the array analysis and the analytical
methods, a total of 40 events were selected from the above
Titration response based on gene level analysis Figure 2
Titration response based on gene level analysis. To calculate the gene level expression values, the median expression 
value was calculated from probe sets common to both isoforms (the F and T probes). The fold change for each gene was 
determined between samples A and B, binned and assessed for correct titration of expression values among the four samples. 
Genes were filtered statistically and those with p values < 0.001 were analyzed. The left graph indicates genes which were 
more highly expressed in sample A than sample B (A > B), and the right graph displays genes which were more highly 
expressed in sample B versus sample A (B > A).
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mentioned categories. First, events were selected from
genes which did not show a significant difference in gene
expression between the universal RNA and the human
brain RNA samples (median of F and T probe values ≤ 1.2
or ≥ -1.2), but did give a B/E ratio of ≥3, indicating that
changes in splicing were occurring. 73% of the events cho-
sen from this list were validated by RT-PCR, and the
results showed that the isoform ratio was altered in both
samples relative to the expression levels from the human
GWSA data. One such event (exon skip) was contained in
the LIM domain 7 gene (Figure 4A) which was found to
be expressed at similar levels in samples A and B; however,
there was an 8 fold change in the B/E ratio for this event.
RT-PCR revealed that only the reference or long form was
expressed in sample A (universal RNA) while both forms
were expressed at approximately equal amounts in sample
B (brain, Figure 4B). These results suggest a downregula-
tion of the reference transcript and an upregulation of the
variant (exon skip) transcript in sample B compared to
sample A. In figure 4B, pooling the reference and variant
intensities for each sample would suggest that overall
gene level expression is similar in samples A and B which
reinforces the idea that examining gene expression alone
would mask the shift in the individual transcripts. The
monitored event is a deletion of exon 28 (Figure 4A)
which causes a predicted frameshift that alters the C-ter-
minal 64 amino acids resulting in the predicted loss of the
LIM domain and overall shortening of the protein by 13
amino acids (Figure 4C).
Events for validation were also selected from the list of
genes which did show significant gene level differences in
expression and also showed a change in the B/E ratio of ≥
3. Overall, all events with conclusive RT-PCR reactions
were validated, showing altered isoform ratios in both
samples. An example of this class of events is illustrated by
the erythrocyte membrane protein band 4.1-like 3
(EPB41L3) gene. At the gene level, EPB41L3 was found to
be more highly expressed in brain than in the universal
RNA sample, but an exon skip event of exon 17 (Figure
5A) was also found to be altered, evidenced by an 11-fold
upregulation of the B/E ratio in brain. RT-PCR analysis
clearly indicates that brain RNA (sample B) contains a sig-
nificantly higher amount of the long form (the reference),
while the short form (the exon skip event) is equal or
potentially higher in the universal RNA sample (sample
A) (Figure 5B). The exon skip event results in an in-frame
deletion, leading to the potential loss of 41 amino acids in
the C-terminal portion of the protein, between the spec-
trin-actin domain (SAB), and the 4.1 C-terminal domain
(Figure 5C).
Discussion
Analysis of gene expression has provided researchers with
an important resource to identify genes involved in differ-
ent biological processes, and has been used to generate
Table 2: Correlation of gene level analysis between the human 
GWSA and the Affymetrix HG-U133 Plus2.0 array.
Genes included # of Genes represented Correlation
all Genes 7,147 0.85
1.5 Fold Change (FC) 3,382 0.90
2.0 FC 2,036 0.92
3.0 FC 1,036 0.933
As intensity values were significantly different due to different 
formats, we compared the fold change between the universal 
reference (sample A) and brain (sample B) between the two designs. 
The correlation between the two platforms was higher when genes 
that were found to be differentially expressed were considered 
distinctly, as would be expected where genes showing no differential 
expression would exhibit a higher variability.
Gene level comparison of human GWSA with the HG-U133  Plus 2.0 array Figure 3
Gene level comparison of human GWSA with the 
HG-U133 Plus 2.0 array. Gene annotations from the 
human GWSA were mapped against the U133 Plus 2.0 array 
and after removing the low expressed genes, 7147 genes 
remained for comparative analysis. Fold changes for each 
gene were calculated between samples A and B for each plat-
form and plotted against each other. Correlation coefficients 
(found in table 1) were calculated based on fold change gene 
sets. A direct comparison of the intensity values was pre-
vented due to the significant differences between the plat-
forms (5 micron versus 11 micron feature size, different 
labeling technology, and probe sequences).
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profiles where the expression level of a predefined set of
genes can help to identify and predict a variety of patho-
logical states and prognoses [14,15]. However, many of
these studies have ignored the large diversity of transcripts
that are generated from each locus by alternative splicing
and miss the rich source of diverse transcripts. Researchers
have treated each gene as a single entity which is inaccu-
rate considering that potentially over 90% of genes
undergo alternative splicing as evidenced by our analysis
and recent reports [16,17]. In an attempt to identify differ-
ent transcripts, studies have been performed where probes
have been reordered into new probe sets to define tran-
scripts more accurately [18-20]. However these studies
suffer from the same flaw, that the original design of the
microarray was not focused on detecting alternative tran-
scripts per se, but to provide an accurate measurement of
the overall expression of each gene, not transcript. In con-
trast, the human Genome-Wide SpliceArray™ (GWSA) is
designed to detect alternatively spliced events through the
use of exon body and junction probes.
Since Johnson and co-workers [21] published the first
human genome-wide microarray that utilized exon-exon
junction probes, several groups have simultaneously pro-
duced microarrays to monitor splice events using similar
probe designs [11,22-24]. The GWSA microarray is the
most comprehensive design commercially available with
over 6 million probes. The array design consists of a max-
imum of 6 probe types targeted to the exon body, exon-
exon junctions, and exon-intron/intron-exon junctions
allowing more complete detection of transcripts, in con-
trast to those commercially available arrays that incorpo-
rate only exon body probes [25] or only junction probes
[24]. The SpliceArray™ probe design simultaneously mon-
itors both isoforms for each splice event and is able to
detect alternative exon, intron retention, alternative splice
acceptor (ASA), and alternative splice donor (ASD)
events. Additionally, the design has the ability to monitor
putative novel skipped exons and unidentified ASA and
ASD events. Although the design is theoretically capable
of detecting all types of events, it does have the limitation
where very short sequence differences (less than 8 bases)
are not captured and these events have been filtered out of
the collection. In addition, the microarray platform itself
has limited space and even at the maximum number of
features, only 6.54 million probes can be included which
limits the number of probes per probe set that can be
designed for any event whether evidenced or predicted.
Furthermore, microarray platforms possess limitations on
the sensitivity to detect very small changes in transcript
expression. A consequence of manufacturing the GWSA
content on the Affymetrix platform is that the cost for
updating the array probe content is significant as it would
require re-manufacturing a custom array and therefore
recent discoveries of novel splice events cannot feasibly be
added to the design. However, it should be pointed out
that the GWSA monitors ~140,000 predicted exon skip
events so although there was no evidence of these exon
skip events at the time the GWSA content was generated,
it indicates that the array has the potential to monitor
newly discovered exon skip events.
Concurrent with the generation of microarray designs
able to detect alternatively spliced transcripts, many ana-
lytical methods have been developed to determine the
extent of alternative splicing and identify the expression
level for each transcript within a gene. We used a simple
approach to identify cases where the ratio of the inclusive
and exclusive isoforms changed dramatically, by calculat-
ing the ratio of probes that were specific for the inclusive
or long form (probe B) versus probes specific for the
exclusive or short form (probe E). This approach was
shown to provide very powerful results when assessed
against PCR validation of the events. It is a simple and
applicable approach that provides strong filtering meth-
ods for real positives, unlike other methodologies which
require an extensive programming and array fitting [22].
Performance of the human GWSA product was evaluated
in this study and the arrays were shown to be highly repro-
ducible, suggesting that the reproducibility is more a func-
tion of the platform and labeling procedures than of the
Table 3: Event analysis of genes grouped by overall gene expression.
Gene Expression Level
(median of F and T)
Event level
(B/E ratio)
Fold Change Set Total Genes Total Events Subset of events with ≥3 Fold Change
x ≥ 3 or ≤ -3 1844 13323 7883
-1.2 ≤ x ≤ 1.2 4434 32917 3012
Genes were classified into two groups: genes that were not differentially expressed between samples A and B (fold changes within the range of -1.2 
≤ x ≤ 1.2), and genes with a greater than 3-fold change (x ≤ -3 or x ≥ 3). In order to determine the differential splicing occurring for each gene, the 
ratio of the long form probe (B) and the short form probe (E) was calculated, and events were selected where the ratio was differentially expressed 
between samples A and B by greater than 3-fold.BMC Genetics 2009, 10:63 http://www.biomedcentral.com/1471-2156/10/63
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probe design. Analysis of the array data at the gene level
proved highly concordant with data produced in the
MAQC project on the HG-U133 Plus 2.0 array. Even
though the platforms were slightly different (the HG-
U133 Plus 2.0 array contains 11 micron features while the
GWSA contains 5 micron features), the genes showed sim-
ilar levels of expression, and importantly, comparable
quantified changes between the universal and brain RNA
samples. High concordance was observed between these
similar platforms even though the probe sets were
designed for different applications. Additionally, the
GWSA and other SpliceArray™ products also provide
splice event information available from the same experi-
ment, exemplified by several recent reports [3,4,26-29].
Validation of specific splice events from the GWSA
hybridizations was performed based on the analysis of the
ratio of the long isoform to the short isoform. This type of
assessment is an important aspect to determining the
extent of alternative splicing as in many cases the ratio of
isoforms will determine the biological response [30-33].
By assessing the statistical power of the ratio, we were able
to validate a high rate of events; overall, 81% of statisti-
cally selected events were validated by RT-PCR. The high
Lim Domain 7 splicing alteration Figure 4
Lim Domain 7 splicing alteration. Lim domain 7 (LMO7) was selected from a set of genes that displayed little difference at 
the gene level between samples A and B, but had event ratios that were significantly higher than 3 fold between these samples, 
indicating a splicing alteration. (A) Using the SpliceArray™ portal (http://portal.splicearray.com) and the associated UCSC 
browser feature, the event is illustrated with the variant sequence used to identify the event (red), the reference sequence 
(black), the probe target regions (blue), and the PCR primers (arrowheads) used to validate the event. (B) RT-PCR results for 
the event validation using the primers indicated in A. R = reference and V = variant (C) Protein domain analysis was done using 
CDART [38] and shows the C terminal Lim domain is missing from the splice variant. (Note that Event ID 4008.010 = Entrez 
Gene ID.ID1 and probe sets are additionally labeled with F, T, B, C, D, or E.)
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rate of validation was found regardless of the overall tran-
scriptional changes identified. Interestingly, almost 60%
of the events identified to have gene level, transcriptional
alterations of 3 fold or more were found to have an event
fold change of 3 fold or more. This indicates that not only
is there a change in overall gene expression, but the tran-
scripts produced are different as generated by alternative
splicing. Surprisingly, genes that showed no change in
their expression levels represented a rich source of alterna-
tively spliced transcripts. Almost 10% of the events among
these genes contained evidence of splicing alterations by
changes in the ratio of the different isoforms. This is an
important finding as it brings to point that genes which
have been ignored because of equivocal expression
between samples actually have important changes that
occur in producing different isoforms. This confirms ear-
lier evidence [34] that illustrates transcriptional activity is
independent of splicing, even though the two processes
function simultaneously and emphasizes the need to
measure both overall gene expression and alternatively
spliced transcripts for greater understanding of biological
processes. The above findings should encourage research-
ers to look more closely at the genes which show no vari-
ation in overall gene expression for important clues into
the mechanisms in pathophysiology and biology.
Erythrocyte membrane protein band 4.1-like 3 (EPB41L3) splicing alteration Figure 5
Erythrocyte membrane protein band 4.1-like 3 (EPB41L3) splicing alteration. EPB41L3 was selected from a set of 
genes that displayed a large difference at the gene level between samples A and B, and, in addition, had event ratios that were 
significantly higher than 3 fold between these samples, indicating a splicing alteration. (A) Using the UCSC browser visualiza-
tion feature of the SpliceArray™ portal (http://portal.splicearray.com), the event is illustrated with the variant sequence used 
to identify the event (red), the reference sequence (black), the probe target regions (blue), and the PCR primers (arrowheads) 
used to validate the event. (B) RT-PCR results for the event validation using the primers indicated in A. R = reference and V = 
variant (C) Protein domain analysis was done using CDART [38] and shows a portion of the C terminal region is removed and 
may affect the function of the protein. (Note that Event ID 23136.004 = Entrez Gene ID.ID1 and probe sets are additionally 
labeled with F, T, B, C, D, or E.)
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Alternative splicing affects not only the structure of the
mRNA but ultimately the structure of the protein pro-
duced. Many exons encode protein domains that can be
removed by an exon skip event [35]. Such an event can
produce proteins that lack a functional domain, domi-
nant negative proteins, constitutively active isoforms, sol-
uble homologues, or can lead to the regulation of the
protein's overall activity by altering its global expression.
The two examples, erythrocyte membrane protein band
4.1-like 3 (EPB41L3), and Lim domain 7 (LMO7)
depicted here show how changes at the transcript level can
be observed with or without gene expression changes,
respectively. Multiple alternative splice variants have been
previously described for LMO7 [36] and the variant
detected here results in deletion of the Lim domain, a pro-
tein-protein interaction domain found in many key regu-
lators of development. EPB41L3 is potentially a critical
growth regulator in meningioma pathogenesis [37] and is
normally expressed at high levels in brain, with lower lev-
els in kidney, intestine, and testis. The function of the
EPB41L3 variant is unknown, yet contains some well
described protein domains, including Ferm domains
found in many cytoskeletal proteins, the N domain found
in ubiquitin-like structural domain, and the C domain
found in tyrosine phosphatases [38]. Different isoforms
certainly will affect the function of these different
domains and potentially the protein, and may play a role
in pathological states.
Conclusion
The identification of expressed transcripts is at the heart of
expression analysis and these examples, as well as recently
identified novel spliced isoforms demonstrating diverse
activity [4,6] illustrate the importance of correct determi-
nation of the expression of each transcript. Array plat-
forms specifically designed to detect the differences in
transcripts along with other novel technologies [39] will
allow researchers to more fully explore the transcriptome
under different physiological and pathological condi-
tions. In short, we have provided a unique platform to
detect isoform diversity in the human transcriptome by
utilizing algorithmically designed novel exon body and
splice junction probes to detect every possible isoform
event. This approach on a genome-wide scale has been
demonstrated to be highly reproducible and quantitative.
Methods
Materials
Total RNA was purchased from Stratagene (Universal
Human Reference RNA, # 740000; sample A) (LaJolla,
CA, USA) and Ambion (Human Brain Total RNA, #
AM7962; sample B) (Austin, TX, USA). Total RNA quality
and concentration were verified using the Agilent 2100
bioanalyzer (Agilent, Santa Clara, CA, USA). Four titration
samples (A, B, C = 75%A+25%B, and D = 25%A+75%B)
were generated as previously described [13] and each sam-
ple was analyzed in triplicate.
The content for the human Genome-Wide SpliceArray™
(GWSA) was designed using Build 35 of the NCBI Human
(genome) reference sequence produced by the Interna-
tional Human Genome Sequencing Consortium and
sequence data from the NCBI GenBank sequence data-
base. Additional information was used from the NCBI
Entrez Gene database in the representation of the genes.
For each gene, a RefSeq was selected as the reference form,
the selection considered which RefSeq (when more than
one was available) covered the largest genomic area to
maximize sequence inclusion (based on mapping against
a genomic range overlapping the selected representative).
Sequences used in the analysis were aligned to the human
genome and data from this alignment was used to create
distinct exon structures. Significant differences from the
reference sequence were detected and probes were
designed to monitor each difference or splice event as pre-
viously described [11]. All splice events included on the
GWSA were subject to manual review to remove those
events that appeared to be indicated by sequence or align-
ment artifact. Additionally, splice events were removed
with the following characteristics: those that resulted in
very small changes (of a few nucleotides) to the transcript;
where the required probes would not conform to Affyme-
trix manufacturing standards; and that would not be
detected by the SpliceArray™ probe configuration. The
human GWSA custom microarrays were manufactured by
Affymetrix (Santa Clara, CA, USA) as a 49 format, 5
micron array containing over 6 million probes which
monitor approximately 229,000 exons and 181,000 junc-
tions. GC probe sets for background correction and posi-
tive and negative control probes were included on the
array. The probes on the array are designed in the sense
orientation and for use with the NuGEN WT-Ovation™
RNA Amplification Systems and FL-Ovation™ Biotin
Module Products. For additional information on Splice-
Array products and probe design, refer to http://
www.splicearray.com.
MicroArray processing: Transcript amplification and 
labeling
Amplified cDNA was prepared using the WT-Ovation™
Pico RNA Amplification System (NuGen product #3300;
Santa Clara, CA, USA) starting with 50 ng of each total
RNA sample, as described by the manufacturer. Briefly,
the RNA is synthesized into double-stranded cDNA using
a SPIA™ DNA/RNA primer. The DNA portion of the
primer binds poly (A) sequence or randomly across the
transcript, and the RNA portion of the primer is incorpo-
rated into an unique DNA/RNA heteroduplex at one end
of the cDNA. RNase H degrades the RNA portion of the
DNA/RNA heteroduplex allowing for additional SPIA™BMC Genetics 2009, 10:63 http://www.biomedcentral.com/1471-2156/10/63
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primer to bind and initiate replication by DNA polymer-
ase. The process of SPIA™ DNA/RNA primer binding,
DNA replication, strand displacement and RNA cleavage
is repeated resulting in isothermal linear amplification of
the cDNA. On average, the cDNA yield from 50 ng of high
quality total RNA ranges from 6 to 10 micrograms. Frag-
mentation and biotin-labeling of the amplified cDNA was
performed using the FL-Ovation™ cDNA Biotin Module
V2 (NuGen product #4200) as per manufacturer's instruc-
tions.
Array hybridization, scanning, and data extraction
Prepared target for each sample was hybridized to the
Affymetrix-formatted SpliceArray™ product using stand-
ard hybridization methods recommended by the manu-
facturer for the 49-format (Affymetrix - Expression
analysis technical manual). The arrays were stained and
washed using the Affymetrix FS450-0001 fluidics protocol
prior to scanning with the Affymetrix GeneChip® Scanner
3000 7G. DAT and CEL images were visually inspected for
anomalies and accurate grid placement. All data are avail-
able through the Gene Expression Omnibus (GEO) data-
base as series accession number GSE17258.
Data analysis
The analysis described here was generated using Partek®
software (http://www.partek.com/). For the comparative
analysis, data for the HG-U133 Plus 2.0 GeneChip was
taken from the MAQC data set publicly available at http:/
/edkb.fda.gov/MAQC/MainStudy/upload/. All array data
was pre-processed which included probe level RMA back-
ground correction, quantile normalization across all
arrays, and Log2 transformation followed by median
polish to summarize probes to obtain the overall score for
each probe set. The data were filtered based on the expres-
sion values of each probe set within the triplicate set for
each sample; if the expression value of a probe set was
below 3.5 (log 2 value) the probe set was removed from
the analysis. In order to identify probe sets that were sig-
nificantly different between samples A and B, a one-way
ANOVA statistical test was performed on normalized and
filtered probe set level intensity values between each
group to generate p-value and fold change data.
To identify genes that were significantly different between
samples A and B, a list of non-redundant evidenced probe
sets were imported into Partek®  software. Non-logged
median values for F and T evidenced probe sets with the
same Entrez Gene ID were calculated to generate an over-
all gene score for each gene. After removing genes which
were expressed at a low level, a one-way ANOVA statistical
test was then performed on the gene level intensity values
between sample groups A and B to generate p-values and
fold changes for each gene.
In order to estimate gene level correlation between the
human GWSA and the HG-U133 Plus 2.0 array data, both
data sets were imported separately and subjected to the
same pre-processing method. For the GWSA data, a gene
score for each sample was generated as described above.
After separately filtering the low-expressing genes in both
data sets, a total of 7,147 common genes were identified.
The log value of the ratio of sample A/sample B of gene
values was calculated for each gene and platform, and a
linear correlation coefficient was calculated between the
GWSA and HG-U133 Plus 2.0.
Event level analysis performed using Partek® software was
based on the calculated ratios between the B probe (spe-
cific to the inclusive isoform or long form) divided by the
E probe (specific to the exclusive or short isoform). This
ratio can be considered a splice score, but has no units.
Only when comparing one sample to another can an
interpretation be made about the differential expression
of the splice variants. A ratio between the non-logged B
and E probe set intensities for each sample was computed
based on normalized and filtered probe set data. Since the
reference and the variant transcripts are monitored by sep-
arate probe sets (B and E) and it is the ratio being calcu-
lated between the two probe sets, there is no need to
normalize for overall gene expression.
A one-way ANOVA statistical test was subsequently per-
formed on the log 2 based ratios between each of the sam-
ple groups to generate p-values and fold change of the B/
E ratio between samples A and B. Similar methods were
used to calculate C/E and D/E ratio, which provided sim-
ilar data.
Using the human GWSA gene level intensity data, two lists
were generated, those genes that displayed no differential
expression change (-1.2 ≤ X ≤ 1.2) between samples A and
B and a second group showing significant gene expression
change, greater than 3 fold change. ANOVA analysis iden-
tified events within these two separate groups having sig-
nificant B/E ratios between samples A and B. Top events
for RT-PCR validation were selected by choosing events
with the highest fold changes, p-values < 0.001, and that
titrated all 4 samples correctly.
RT-PCR Processing
First strand cDNAs were prepared using a random priming
protocol starting with 5 μg of the individual RNA samples
using the High Capacity cDNA Archive Kit (Applied Bio-
systems; Foster City, CA, USA). cDNA was prepared from
both the human normal brain and universal human refer-
ence RNA samples and the quality and consistency were
assessed by determining the levels of ribosomal protein
B probe setsample Gene Expressionsample
E probe setsample G
/
/ e ene Expressionsample
B probe set E probe set sample sample = /BMC Genetics 2009, 10:63 http://www.biomedcentral.com/1471-2156/10/63
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P0 by RT-PCR. Additionally, samples were normalized by
the level of ribosomal P0 for validation of each splice
event.
Lasergene/Primer Select (DNAstar) software was used for
primer design. Primer sequences will be provided upon
request. RT-PCR amplification was performed using a
cDNA dilution with the equivalent of 17 ng of total RNA
for each reaction. Promega 2× PCR Master Mix (Madison,
WI, USA) was used for each 50 ul reaction with forward
and reverse primer at a final concentration of 0.3 uM. A
"touchdown" cycling program was used to amplify prod-
ucts (annealing temp 65°C-60°C, 5 cycles, and 60°C, 35
cycles). 12 μl of PCR products were analyzed using either
2% Agarose or 3% Metaphor gels.
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